Imago Biosciencesgranted fast track designation for IMG-7289 in myelofibrosis

Imago BioSciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of IMG-7289 (bomedemstat) for the treatment of myelofibrosis.

“Myelofibrosis remains a major unmet clinical need imposing on patients a great burden of disease. IMG-7289 shows promise to meet this need of relieving patient’s symptoms and improving their quality of life,” said Hugh Young Rienhoff, Jr. M.D., chief executive officer of Imago BioSciences. “Under the Fast Track designation, we seek to expeditiously advance the clinical development of IMG-7289.”

According to the FDA, “Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious conditions.” Click here to learn more about Fast Track.

Receive updates on the latest MPN news & events.